StockData

Nika Pharmaceuticals, Inc (NIKA) stock

NIKAOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 0/30
$0.41+0.00 (0.00%)

Close on Oct 16, 2026Market cap $431.19MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$431.19M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$78.14K
EPS, diluted
$0.00
Book value per share
-$0.00
Diluted shares
1.05B

Trading

Previous close
$0.41
Open
$0.41
Day's range
$0.41 – $0.41
Volume
0

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodNIKAS&P 500DifferenceNIKA per yearS&P 500 per year
1 month0.0%+1.5%−1.5 pts
3 months-46.7%+1.9%−48.6 pts
Year to date+7.9%+12.8%−4.9 pts
1 year-14.4%+16.8%−31.2 pts

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$78.14K

Net income

-$78.14K

EPS, diluted

$0.00
Reported periodTrailing twelve months

About Nika Pharmaceuticals

Pharmaceutical Preparations

Nika Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and distributing prescription therapies and dietary food supplements. Its primary pharmaceutical assets include Thymus Nuclear Glycoprotein, intended for treating human immunodeficiency virus infections, alongside treatments developed on an inactivated pepsin fraction platform. The company also distributes multiple dietary supplement lines, including Carotilen, Physiolong, Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron, designed for cellular protection, immune stimulation, and physical convalescence. Its offerings serve individuals undergoing physical recovery as well as patients managing chronic viral conditions.

Company profile, executives and history

Nika Pharmaceuticals stock: common questions

What is Nika Pharmaceuticals's stock price?

NIKA closed at $0.41 on Oct 16, 2026, up 0.00% on the day.

What is Nika Pharmaceuticals's market cap?

Nika Pharmaceuticals was worth $431.19M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.

What is NIKA's P/E ratio?

Nika Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

Does Nika Pharmaceuticals pay a dividend?

No. Nika Pharmaceuticals has not paid a cash dividend over the last twelve months.

How has NIKA stock performed over the past year?

Including dividends, NIKA returned -14.4% over the past year, against +16.8% for the S&P 500.

Who are Nika Pharmaceuticals's competitors?

Companies most similar to Nika Pharmaceuticals by business, industry and size include BDPT, JAGX, ANIP, KMDA, GRFS.

See a number that looks wrong?